Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details)

v3.23.1
Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Level 3 significant unobservable inputs
$ in Thousands
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Equity and Warrant Investments    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 91,839 $ 85,966
Valuation Market Approach | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 30,445 30,086
Valuation Market Approach | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 13,711 $ 12,479
Valuation Market Approach | Minimum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.0332  
Valuation Market Approach | Maximum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.3408  
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 13.3 12.4
Market Comparable Companies | Minimum | EBITDA Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 13.3 12.4
Market Comparable Companies | Minimum | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 0.6 0.7
Market Comparable Companies | Minimum | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 0.3 0.6
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 1.6 1.6
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.0332 0.0811
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1]   0.0811
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 13.3 12.4
Market Comparable Companies | Maximum | EBITDA Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 13.3 12.4
Market Comparable Companies | Maximum | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 20.6 16.1
Market Comparable Companies | Maximum | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 10.3 8.8
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 1.6 1.6
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.3366 0.2890
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1]   0.3270
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 13.3 12.4
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 13.3 12.4
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 8.6 7.4
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 3.7 3.4
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 1.6 1.6
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1],[3] 0.2421 0.1979
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1],[3] 0.2384 0.1897
Liquidation | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 0 $ 0
Liquidation | Minimum | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 2.2 2.1
Liquidation | Minimum | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2]   6.2
Liquidation | Minimum | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.8600 0.8500
Liquidation | Minimum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1]   90.00
Liquidation | Maximum | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2] 2.2 2.1
Liquidation | Maximum | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2]   6.2
Liquidation | Maximum | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1] 0.8600 0.8500
Liquidation | Maximum | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1]   90.00
Liquidation | Weighted Average | Revenue Multiple | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3] 2.2 2.1
Liquidation | Weighted Average | Revenue Multiple | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [2],[3]   6.2
Liquidation | Weighted Average | Discount for Lack of Marketability | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1],[3] 0.8600 0.8500
Liquidation | Weighted Average | Discount for Lack of Marketability | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [1],[3]   90.00
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4]   (0.9782)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4]   0.1634
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [3],[4]   (0.0886)
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [3],[4]   (0.1669)
Market Adjusted OPM Backsolve | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 12,467 $ 13,795
Market Adjusted OPM Backsolve | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 7,299 $ 6,934
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4] (0.8577) (0.9782)
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4] (0.7190)  
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4] 0.1232 0.6643
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [4] 0.4442  
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [3],[4] (0.1851)  
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [3],[4] (0.0824)  
Discounted Cash Flow | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 24,595 $ 19,153
Discounted Cash Flow | Minimum | Measurement Input, Discount Rate | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [5] 0.1964 0.1772
Discounted Cash Flow | Maximum | Measurement Input, Discount Rate | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [5] 0.3115 0.3013
Discounted Cash Flow | Weighted Average | Measurement Input, Discount Rate | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [3],[5] 0.2566 0.2446
Other | Equity Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments [6] $ 3,322 $ 3,513
Other | Warrant    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments [6]   6
Investments [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 2,968,651 2,795,444
Investments [Member] | Debt Maturing Within One Year    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 97,431 93,597
Investments [Member] | Debt Investments - Imminent Payoff    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments [7] 235,746 77,676
Investments [Member] | Valuation Cost Approach    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 332,001 392,168
Investments [Member] | Valuation Market Approach | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 993,806 903,427
Investments [Member] | Valuation Market Approach | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 911,752 967,108
Investments [Member] | Valuation Market Approach | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 3,108 3,006
Investments [Member] | Valuation Market Approach | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 347,961 328,393
Investments [Member] | Liquidation | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments 16,343  
Investments [Member] | Liquidation | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments [8] 1,193 1,671
Investments [Member] | Liquidation | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 7,774 [8] $ 8,042
Investments [Member] | Liquidation | Minimum | Collateral Recoverability | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.2500  
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8] 0.1000 0.0500
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8] 0.2000 0.2000
Investments [Member] | Liquidation | Maximum | Collateral Recoverability | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.4000  
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8] 0.9000 0.8000
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8] 0.8000 0.8000
Investments [Member] | Liquidation | Weighted Average | Collateral Recoverability | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.3295  
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8],[9] 0.7954 0.4829
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [8],[9] 0.8000 0.8000
Investments [Member] | Valuation Income Approach | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Investments $ 21,536 $ 20,356
Investments [Member] | Valuation Income Approach | Minimum | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.0100 0.0100
Investments [Member] | Valuation Income Approach | Maximum | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.5000 0.5000
Investments [Member] | Valuation Income Approach | Weighted Average | Probability weighting of alternative outcomes | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.3524 0.3579
Investments [Member] | Market Comparable Companies | Hypothetical Market Yield | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1469  
Investments [Member] | Market Comparable Companies | Premium/(Discount) | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.0075  
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1161 0.1174
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1225 0.1205
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input   0.1471
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1378 0.1368
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input (0.0150) (0.0075)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input (0.0075) (0.0100)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input   0.0075
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input (0.0200) (0.0200)
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1951 0.1904
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.2011 0.1853
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input   0.1471
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.1714 0.1849
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.0300 0.0175
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.0300 0.0150
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input   0.0075
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 0.0100 0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.1455 0.1517
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.1552 0.1521
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.1469 0.1471
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.1387 0.1482
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Pharmaceuticals    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.0000 0.0001
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.0030 0.0020
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Sustainable And Renewable Technology    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] 0.0075 0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Lower Middle Market    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input [9] (0.0044) (0.0043)
[1] Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
[2] Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
[3] Weighted averages are calculated based on the fair market value of each investment.
[4] Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
[5] The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
[6] The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.
[7] Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
[8] The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.
[9] The weighted averages are calculated based on the fair market value of each investment.